The firm's technology uses DNA sequencing, artificial intelligence, and a microbial database to interpret soil health and identify potential disease risk.
ExcitePCR's technology detects pathogens in 30 minutes or less using a backpack-sized device, integrating sample prep with PCR and RIF technology in a disposable cartridge.
CRISPR/Cpf1 can serve as an alternative or even complementary genome editing technology to CRISPR/Cas9, which Monsanto has also licensed from the Broad.
